Food and drink composition containing peptide and / or its salt, method for producing same, use of type II collagen hydrolysate, composition for inhibiting bone resorption, and use of chicken extract

A food and drink composition with a specific peptide from avian cartilage type 2 collagen hydrolyzate and chicken extract addresses inflammation and bone resorption, offering a safe and effective solution for conditions like osteoarthritis and osteoporosis.

JP7590437B2Active Publication Date: 2024-11-26SUNTORY HLDG LTD
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
JP2022538740
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-12-27
Filing Date
2020-06-26
Publication Date
2024-11-26
Estimated Expiration
2040-06-26

Smart Images

  • Figure 0007590437000009
    Figure 0007590437000009
  • Figure 0007590437000010
    Figure 0007590437000010
  • Figure 0007590437000011
    Figure 0007590437000011
Patent Text Reader

Abstract

The present invention aims to provide a novel food and beverage composition containing a peptide that has anti-inflammatory activity.The present invention aims to provide a novel food and beverage composition containing a peptide that has bone resorption inhibitory activity.The present invention aims to provide a novel composition for inhibiting bone resorption. [Solution] The present invention relates to a food or beverage composition containing a peptide consisting of the amino acid sequence represented by SEQ ID NO: 1 and / or a salt thereof. The present invention also relates to a composition for inhibiting bone resorption containing chicken extract as an active ingredient.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a food and drink composition containing a peptide and / or a salt thereof and a method for producing the same. The present invention also relates to a type II collagen hydrolysate containing a peptide and / or a salt thereof for producing an anti-inflammatory composition. The present invention also relates to use of a peptide and / or a salt thereof for producing a composition for inhibiting bone resorption. The present invention also relates to a composition for inhibiting bone resorption. The present invention also relates to use of a chicken extract for producing a composition for inhibiting bone resorption. [Background technology]

[0002] Collagen has been widely used as gelatin in the food industry. Collagen, an animal protein, is the main component of the dermis and connective tissue, and has been attracting attention in recent years in the medical and beauty fields. In general, it is difficult to efficiently utilize high molecular weight collagen in the body even if it is orally ingested. In recent years, collagen peptides have been developed by hydrolyzing high molecular weight collagen to reduce its molecular weight so that it can be ingested in the body, and foods and beverages containing collagen peptides have also been developed.

[0003] Inflammation is a phenomenon in which cell damage causes the release of histamine and kinins, leading to vasodilation, increased capillary permeability, and the concentration of macrophages at the site of inflammation, resulting in increased blood flow to the infected site, edema, migration of immune cells and antibodies, pain, fever, etc.

[0004] In recent years, research has been conducted into ingredients that can suppress the expression of inflammation-related proteins in order to effectively alleviate inflammation. Anti-inflammatory drugs with various mechanisms, including nonsteroidal anti-inflammatory drugs (NSAIDs) and steroidal anti-inflammatory drugs (SAIDs), have been developed, but they have concerns about side effects. Therefore, there is still a demand for safer ingredients that have anti-inflammatory effects.

[0005] For example, Patent Document 1 discloses an anti-inflammatory composition that contains, as an active ingredient, a peptide derived from telomerase having anti-inflammatory activity.

[0006] Osteoporosis is a disease in which low bone mass increases bone fragility and the risk of fracture. Normally, bone remodeling occurs in which old bone is absorbed by osteoclasts and new bone is created by osteoblasts. Osteoporosis develops when the balance of this bone remodeling is disrupted.

[0007] Female hormone drugs and bisphosphonate drugs are used to treat osteoporosis, and food ingredients such as soy isoflavones, vitamin K, and calcium have been reported to improve bone metabolism and bone density. However, due to concerns about the cost and side effects, it is said that as many as 45% of patients stop taking the medication as prescribed within a year. Therefore, there is a demand for ingredients that can be taken orally, safely and easily, to improve bone metabolism and increase bone density.

[0008] For example, Patent Document 2 discloses an agent for improving bone metabolism or bone density, which contains cells and / or a culture product of a Bacillus microorganism as an active ingredient. [Prior art documents] [Patent documents]

[0009] [Patent Document 1] Special Publication No. 2015-525768 [Patent Document 2] JP 2017-226649 A Summary of the Invention [Problem to be solved by the invention]

[0010] An object of the present invention is to provide a novel food and drink composition containing a peptide. Another object of the present invention is to provide a food and drink composition having an anti-inflammatory effect. Another object of the present invention is to provide a food and drink composition having a bone resorption inhibiting effect. Another object of the present invention is to provide a novel composition for inhibiting bone resorption. [Means for solving the problem]

[0011] The present inventors have found that a composition containing a peptide consisting of the amino acid sequence represented by SEQ ID NO: 1 and / or a salt thereof has a bone resorption inhibitory effect. Furthermore, the present inventors have found that a type II collagen hydrolysate from chicken cartilage containing a peptide consisting of the amino acid sequence represented by SEQ ID NO:1 and / or a salt thereof has anti-inflammatory activity. The present inventors have also found that chicken extract has an inhibitory effect on bone resorption.

[0012] That is, the present invention is as follows. [1] A food or beverage composition comprising a peptide consisting of the amino acid sequence represented by Gly-Pro-Glu-Gly-Ala-Pro-Gly-Lys-Asp (sequence number 1) and / or a salt thereof. [2] The food and beverage composition according to [1] above, wherein the peptide and / or salt thereof is a peptide and / or salt thereof derived from a type II collagen hydrolysate of chicken cartilage. [3] The food and beverage composition according to [1] or [2] above, which contains a type II collagen hydrolysate from chicken cartilage. [4] The food or drink composition according to any one of the above [1] to [3], further comprising an animal extract and / or a plant extract. [5] The food and beverage composition according to [4] above, wherein the animal extract is chicken extract. [6] The food and beverage composition according to [5] above, which contains one or more of carnosine and / or anserine and / or salts thereof. [7] The food and beverage composition according to [6] above, wherein the weight ratio of the total weight of the carnosine, anserine and their salts in terms of carnosine and anserine to the weight of the peptide and / or its salt in terms of peptide (total of carnosine and anserine / peptide) is 1,000,000 / 1 to 100 / 1. [8] The food or drink composition according to any one of the above [1] to [7], which is used to suppress inflammation. [9] The food and beverage composition according to any one of [1] to [8] above, which suppresses the production of at least one cytokine selected from the group consisting of macrophage inflammatory protein-1 (MIP-1), monocyte chemotactic protein-1 (MCP-1), interleukin-6 (IL-6), interleukin-7 (IL-7), interleukin-8 (IL-8), interleukin-9 (IL-9), interleukin-12 (IL-12), and RANTES (regulated on activation, normal T cell expressed and secreted).

[10] The food or drink composition according to any one of [1] to [9] above, which is used for preventing or ameliorating an inflammatory condition or disease.

[11] The food or drink composition according to any one of the above [1] to

[10] , which is used to inhibit the bone resorption activity of osteoclasts.

[12] The food or drink composition according to any one of [1] to

[11] above, which is used for preventing or improving a condition or disease associated with bone mass loss.

[13] The food and beverage composition according to

[12] above, wherein the condition or disease associated with bone mass loss is osteoporosis or osteopenia.

[14] A method for producing a food or beverage composition, comprising a step of blending a peptide having an amino acid sequence represented by Gly-Pro-Glu-Gly-Ala-Pro-Gly-Lys-Asp (sequence number 1) and / or a salt thereof.

[15] The method according to

[14] above, wherein the step is a step of blending a type II collagen hydrolysate of chicken cartilage containing the peptide and / or a salt thereof.

[16] The method for producing the composition according to

[14] or

[15] above, further comprising a step of blending an animal extract and / or a plant extract.

[17] The method according to

[16] above, wherein the animal extract is chicken extract.

[18] The method according to

[17] above, wherein the chicken extract contains one or more of carnosine and / or anserine and / or salts thereof.

[19] Use of a type II collagen hydrolysate from chicken cartilage containing a peptide consisting of the amino acid sequence represented by Gly-Pro-Glu-Gly-Ala-Pro-Gly-Lys-Asp (sequence number 1) and / or a salt thereof for the production of an anti-inflammatory composition.

[20] Use of a peptide consisting of the amino acid sequence represented by Gly-Pro-Glu-Gly-Ala-Pro-Gly-Lys-Asp (sequence number 1) and / or a salt thereof for producing a composition for inhibiting bone resorption.

[21] A composition for inhibiting bone resorption comprising chicken extract as an active ingredient.

[22] The composition for inhibiting bone resorption according to

[21] above, which contains one or more of carnosine and / or anserine and / or salts thereof.

[23] Use of chicken extract for producing a composition for inhibiting bone resorption. Effect of the Invention

[0013] According to the present invention, a novel food and drink composition containing a peptide and / or a salt thereof can be provided. The food and drink composition of the present invention can be used to suppress inflammation and arthralgia. In addition, the food and drink composition of the present invention can be used to suppress bone resorption activity. In addition, according to the present invention, a novel composition for inhibiting bone resorption containing chicken extract as an active ingredient can be provided. The peptide and / or a salt thereof consisting of the amino acid sequence represented by SEQ ID NO: 1, and chicken extract can be ingested as food and drink, etc., and have the advantage of being highly safe. [Brief description of the drawings]

[0014] [Figure 1] FIG. 1 is a flow diagram illustrating a simplified method for preparing type II collagen hydrolysate of chicken cartilage. [Diagram 2] FIG. 2 is a graph showing the inhibitory effect of chicken cartilage type II collagen hydrolysate (HCII) and chicken extract (CE) added to cells with induced inflammation on the production of the inflammatory marker MIP-1β. [Diagram 3]FIG. 3 is a graph showing the synergistic effect of a combination of chicken cartilage type II collagen hydrolysate (HCII) and chicken extract (CE) in suppressing the production of the inflammatory marker MIP-1β. [Figure 4] FIG. 4 is a graph showing the inhibitory effect of fractions P1 and P2, out of seven fractions obtained by fractionating type II collagen hydrolysate (HCII) from chicken cartilage, on the production of the inflammatory marker MIP-1β. [Diagram 5] FIG. 5 is a graph showing the inhibitory effect of chicken cartilage type II collagen hydrolysate (HCII) added to cells with induced inflammation on the production of inflammatory markers. [Figure 6] FIG. 6 is a graph showing the effect of chicken cartilage type II collagen hydrolysate (HCII) and chicken extract (CE) on suppressing the production of the inflammatory marker MCP-1, the synergistic effect of the combination of HCII and CE, and the synergistic effect of the combination of the peptide GPEGAPGKD and CE. [Figure 7-1] 7-1(a), (b), and (c) are graphs showing the synergistic effect of the combination of HCII and CE on suppressing the production of inflammatory markers IL-6, IL-8, and IL-9, and the synergistic effect of the combination of peptide GPEGAPGKD and CE. [Figure 7-2] Figures 7-2(d), (e), and (f) are graphs showing the synergistic effect of the combination of HCII and CE on inhibiting the production of inflammatory markers MCP-1, MIP-1β, and RANTES, and the synergistic effect of the combination of peptide GPEGAPGKD and CE. [Figure 8] FIG. 8 is a graph showing the effect of chicken cartilage type II collagen hydrolysate (HCII) on the inhibition of bone resorption activity. [Figure 9] FIG. 9 is a graph showing the effect of type II collagen hydrolysate of chicken cartilage (HCII) and several of the seven fractions obtained by fractionating type II collagen hydrolysate of chicken cartilage (HCII) and their combinations (specifically, each of fractions P1 to P5, the combination of fraction P6 and fraction P7, the combination of fraction P1 and fraction P2, the combination of fraction P3 and fraction P4, and the combination of fractions P1 to P7) on inhibiting bone resorption activity. [Figure 10] FIG. 10 is a graph showing the effect of type II collagen hydrolysate from chicken cartilage (HCII), a combination of HCII fractions P1 and P2, and a peptide (GPEGAPGKD) consisting of the amino acid sequence represented by sequence number 1, in suppressing bone resorption activity. [Figure 11] FIG. 11 is a graph showing the dose-dependent effect of chicken extract (CE) on the inhibition of bone resorption activity. [Figure 12] Fig. 12(a) is a graph showing the effect of intake (14 days) of type II collagen hydrolysate of chicken cartilage (HCII) on VAS pain scores on days 7 and 14 in each treatment group of the protocol-compliant population (n=151). Fig. 12(b) is a graph showing the effect of intake (14 days) of type II collagen hydrolysate of chicken cartilage (HCII) on VAS pain scores on days 7 and 14 in each treatment group of subjects (n=8) whose number of resistance training sessions was less than the 10th percentile of the entire resistance training period. [Figure 13] FIG. 13 is a graph showing the effect of ingestion of a combination of chicken cartilage type II collagen hydrolysate (HCII) and chicken extract (CE) (24 weeks) on bone mass in the left hip joint. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0015] According to one aspect of the present invention, the food and beverage composition of the present invention contains a peptide consisting of the amino acid sequence represented by Gly-Pro-Glu-Gly-Ala-Pro-Gly-Lys-Asp (SEQ ID NO: 1) and / or a salt thereof (hereinafter, "a peptide consisting of the amino acid sequence represented by Gly-Pro-Glu-Gly-Ala-Pro-Gly-Lys-Asp (SEQ ID NO: 1)" may be referred to as "Pep1" or "GPEGAPGKD").

[0016] <Peptide> Pep1 may be a peptide obtained by hydrolyzing animal or plant proteins, etc., or may be artificially synthesized. Pep1 is preferably a peptide derived from a type II collagen hydrolysate, more preferably a peptide derived from a type II collagen hydrolysate of chicken cartilage. Pep1 may be used in a purified form, or may be contained in the composition in the form of a type II collagen hydrolysate of chicken cartilage containing Pep1. In a preferred embodiment, the food and drink composition of the present invention contains a type II collagen hydrolysate of chicken cartilage. When the food and drink composition of the present invention contains a type II collagen hydrolysate of chicken cartilage, the anti-inflammatory effect and bone resorption inhibitory effect are enhanced.

[0017] Pep1 can be contained in the food and beverage composition of the present invention in the form of a salt with an inorganic or organic acid or a salt with an inorganic or organic base. The acid or base can be selected depending on the use of the salt, but in consideration of the use in food and beverage, the following salts acceptable for food and beverage are preferred. Examples of the inorganic acid salts include hydrochloride, nitrate, sulfate, methanesulfonate, p-toluenesulfonate, etc. Examples of the organic acid salts include salts with dicarboxylic acids such as oxalic acid, malonic acid, succinic acid, maleic acid, and fumaric acid, and salts with monocarboxylic acids such as acetic acid, propionic acid, and butyric acid. Examples of the inorganic bases include hydroxides, carbonates, and bicarbonates of sodium, lithium, calcium, magnesium, and aluminum, and ammonia. Examples of salts with organic bases include mono-, di-, or tri-alkylamine salts such as methylamine, dimethylamine, and triethylamine; mono-, di-, or tri-hydroxyalkylamine salts; guanidine salts; and N-methylglucosamine salts.

[0018] <Chicken cartilage type II collagen hydrolysate> The food and drink composition of the present invention preferably contains a type II collagen hydrolysate from chicken cartilage. A type II collagen hydrolysate of chicken cartilage (hereinafter, "type II collagen hydrolysate of chicken cartilage" may be referred to as "HCII") can be obtained by hydrolyzing type II collagen with an enzyme or the like. Type II collagen can be extracted from chicken cartilage by a known method. In addition, the type II collagen hydrolysate of chicken cartilage used in the present invention can be prepared from cartilage using a conventional technique used in this field. For example, a type II collagen hydrolysate can be obtained by enzymatically treating chicken cartilage. Specifically, a type II collagen hydrolysate can be prepared by (1) a pretreatment step of heating chicken cartilage in a liquid, and (2) a step of enzymatically treating the chicken cartilage after the pretreatment step. The enzyme used in the above step (2) is not particularly limited as long as it is an enzyme commonly used in this field, and examples of the enzyme that can be used include collagenase, papain, bromelain, actinidin, ficin, cathepsin, pepsin, chymosin, trypsin, protease, subtilisin, aminopeptidase, endopeptidase, exopeptidase, and enzyme preparations containing a mixture of these enzymes. However, the method for preparing a type II collagen hydrolysate is not limited to the enzymatic treatment method.

[0019] For the type II collagen hydrolysate of chicken cartilage, a solution obtained by hydrolyzing chicken cartilage may be used, or a concentrate or dry powder thereof, or a purified product thereof may be used. As the purified product of type II collagen hydrolysate of chicken cartilage, for example, a solution obtained by hydrolyzing chicken cartilage is subjected to ultrafiltration, membrane treatment, liquid separation operation, or fractionation treatment using resin or the like to increase the degree of purification, and then the type II collagen hydrolysate of chicken cartilage containing Pep1 and / or a salt thereof may be powdered by freeze-drying, spray-drying, or the like.

[0020] A type II collagen hydrolysate from chicken cartilage is generally a peptide mixture containing Pep1 and / or a salt thereof, and can also be referred to as a collagen peptide derived from type II collagen. The type II collagen hydrolysate of chicken cartilage preferably has a weight average molecular weight of 100 to 20,000, more preferably 2,000 to 8,000, and even more preferably 3,000 to 7,000. The molecular weight and weight average molecular weight can be measured by Eurofins HPAEC-PAD method.

[0021] In one aspect, a type II collagen hydrolysate from chicken cartilage is fractionated according to molecular weight size by a method such as gel filtration, and the resulting fraction containing Pep1, or a combination of the fraction containing Pep1 and one or more other fractions, can be used in the food and beverage composition of the present invention. As the fractions obtained by fractionating the type II collagen hydrolysate of chicken cartilage used in the food and drink composition of this embodiment, a fraction (fraction 1) having a molecular weight of less than 3100 and a weight average molecular weight of 1200 to 1400, and a fraction (fraction 2) having a molecular weight of less than 2600 and a weight average molecular weight of 950 to 1150 are preferred. The food and drink composition of this embodiment preferably contains a combination of fraction 1 and fraction 2. Pep1 is usually contained in fraction 1 and fraction 2 derived from the type II collagen hydrolysate of chicken cartilage.

[0022] It is preferable that the food and drink composition of the present invention further contains an animal extract and / or a plant extract. Examples of animal extracts include extracts from mammals such as cows, pigs, sheep, and goats, birds such as chickens, quails, ducks, and geese, shellfish, insects, fish, mollusks, and crustaceans, etc. Examples of plant extracts include extracts from tea, fruit juice extracts and concentrates thereof, vegetable extracts and concentrates thereof, soybean and nut extracts, etc. Among the above animal extracts and plant extracts, the animal extract is preferred, the avian extract is more preferred, the poultry extract is even more preferred, and the chicken extract is particularly preferred. When the food and drink composition of the present invention contains the chicken extract, the inflammation suppressing effect is further enhanced.

[0023] <Chicken extract> The chicken extract (hereinafter sometimes referred to as CE) used in the present invention may be an extract obtained by heating chicken meat as a raw material in a liquid, or a commercially available product. The raw material may contain bones, cartilage, legs, etc., but preferably does not contain chicken heads or internal organs.

[0024] Commercially available chicken extracts (CEs) include, for example, "BEC Brand's Essence of Chicken" (manufactured by Suntory Food Asia Co., Ltd.) and "Scotch TM Essence of Chicken (made by Scotch Industrial (Thailand)), Quaker Essence of chicken (made by Standard Foods Corporation (Taiwan)), Chicken stock and broth of SWANSON TM (manufactured by Campbell Soup Company (NYSE:CPB)), "Drip Chicken Essence (manufactured by Eu Yan Sang International (Singapore))", "Boned Chicken Tonic (manufactured by Eu Yan Sang International (Singapore))", "Boiled Essence of Chicken (manufactured by Lao Xie Zhen (Taiwan))" and the like. Any of the commercially available products may be used, but it is preferable to use BEC Brand's Essence of Chicken.

[0025] When the chicken extract used in the present invention is produced by hot water extraction, it can be produced by a conventional method used in this field. For example, chicken extract can be produced by performing normal pressure extraction and / or pressurized extraction using a liquid at 100°C or higher, preferably 125°C or higher, and subjecting the obtained extract to membrane treatment or filtration. Specifically, the chicken extract can be obtained by (3) a pretreatment step of heating chicken meat in a liquid to remove water-soluble proteins contained therein, and (4) a step of replacing the liquid after the above pretreatment and heating again. Note that the heat treatment in steps (3) and (4) is preferably performed in a solvent to prevent the raw chicken meat from burning. As the solvent, water, ethanol, or a mixture thereof is preferably used. The chicken extract includes the extract obtained by the above-mentioned method, its dilution, concentrate or dry powder, and purified products thereof. As the purified product, for example, the chicken extract extract is subjected to ultrafiltration, membrane treatment, liquid separation operation, or fractionation treatment using resin or the like to increase the degree of purification. After increasing the degree of purification of the chicken extract, it may be powdered by freeze drying, spray drying, or the like.

[0026] The chicken extract used in the present invention preferably contains one or more of carnosine and / or anserine and / or their salts. Carnosine is a dipeptide of β-alanine and histidine, which is β-alanyl-histidine. Anserine is a dipeptide in which the histidine moiety is methylated to become β-alanyl-1-methylhistidine. Examples of salts of carnosine and salts of anserine include the same as the salts of Pep1 described above.

[0027] When the food and drink composition of the present invention contains carnosine and / or its salt, the content of carnosine and / or its salt in the composition is, for example, preferably 0.00001% by weight or more, more preferably 0.0001% by weight or more, and preferably 10% by weight or less, more preferably 1% by weight or less, calculated as carnosine. In one embodiment, the content of carnosine in the composition is, for example, preferably 0.00001 to 10% by weight, more preferably 0.0001 to 1% by weight.

[0028] When the food and drink composition of the present invention contains anserine and / or a salt thereof, the content of anserine and / or a salt thereof in the composition is, for example, preferably 0.00001% by weight or more, more preferably 0.0001% by weight or more, and preferably 10% by weight or less, more preferably 1% by weight or less, calculated as anserine. In one embodiment, the content of anserine in the composition is, for example, preferably 0.00001 to 10% by weight, more preferably 0.0001 to 1% by weight.

[0029] Carnosine and anserine can be quantified, for example, by HPLC. The food and drink composition of the present invention more preferably contains carnosine and anserine.

[0030] The weight ratio of the total weight of the carnosine, anserine and their salts calculated as carnosine and anserine to the weight of Pep1 and / or their salts calculated as peptide (total of carnosine and anserine / Pep1) is preferably 1,000,000 / 1 to 1 / 15,000. The weight ratio is more preferably 1,000,000 / 1 to 100 / 1, and even more preferably 100,000 / 1 to 1,000 / 1.

[0031] The weight ratio of the above-mentioned chicken cartilage type II collagen hydrolysate (in terms of solid content) to the above-mentioned carnosine, anserine and their salts in terms of carnosine and anserine (HCII / total of carnosine and anserine) is preferably 20 / 1 to 1 / 5. The above-mentioned weight ratio is more preferably 15 / 1 to 1 / 3.

[0032] The content of each component contained in the food and beverage composition of the present invention is not particularly limited, and can be set depending on the form of the composition, etc. In one aspect, the content of Pep1 and / or a salt thereof in the food and beverage composition of the present invention is preferably 0.00001% by weight or more, more preferably 0.0001% by weight or more, and preferably 1% by weight or less, more preferably 0.1% by weight or less, calculated as Pep1. In one aspect, the content of Pep1 and / or a salt thereof in the composition is preferably 0.00001 to 1% by weight, more preferably 0.0001 to 0.1% by weight.

[0033] In one embodiment, the content of the type II collagen hydrolysate of chicken cartilage (in terms of solid content) in the food and beverage composition of the present invention is preferably 0.1% by weight or more, more preferably 0.5% by weight or more, and preferably 99% by weight or less, more preferably 90% by weight or less. In one embodiment, the content of the type II collagen hydrolysate of chicken cartilage (in terms of solid content) in the composition is preferably 0.1 to 99% by weight, more preferably 0.5 to 90% by weight. As used herein, the content of type 2 collagen hydrolysate of chicken cartilage includes Pep1.

[0034] In one embodiment, the content of the chicken extract (in terms of solid content) in the food and beverage composition of the present invention is preferably 0.1% by weight or more, more preferably 0.5% by weight or more, and is preferably 99% by weight or less, more preferably 90% by weight or less. In one embodiment, the content of the chicken extract (in terms of solid content) in the composition is preferably 0.1 to 99% by weight, more preferably 0.5 to 90% by weight.

[0035] Examples of food and drink compositions include general food and drink, functional foods, health functional foods, special purpose foods, nutritional supplements, dietary supplements, supplements, etc. The form of the food and drink is not particularly limited, and may be, for example, a solid food or a liquid food. A beverage is preferred.

[0036] The food and beverage composition of the present invention may contain various diluents, acidulants, antioxidants, stabilizers, preservatives, flavorings, emulsifiers, colorants, seasonings, pH adjusters, nutritional enhancers, etc. that are permitted as additives to foods and beverages.

[0037] The food and drink composition of the present invention is preferably used for non-therapeutic purposes. The term "non-therapeutic" refers to a concept that does not include medical procedures, i.e., surgery, treatment or diagnosis of humans.

[0038] <Anti-inflammatory composition> In one embodiment, the food and beverage composition of the present invention can be used to suppress inflammation. The food and beverage composition of the present invention may be an anti-inflammatory composition, and may be an anti-inflammatory composition containing Pep1 and / or a salt thereof as an active ingredient.

[0039] In order to obtain the anti-inflammatory effect of the present invention, the type II collagen hydrolysate of chicken cartilage containing Pep1 and / or a salt thereof and optionally a chicken extract are blended into the food and drink composition, as in the above-mentioned food and drink composition. The type II collagen hydrolysate of chicken cartilage containing Pep1 and / or a salt thereof and the chicken extract may be used as is, or may be blended in the form of a concentrate, dried powder or a highly refined product as described above, as long as the effect of the present invention is not impaired. The additives and the like that can be used are the same as those described above.

[0040] The intake amount of the food and drink composition of the present invention is not particularly limited. In one embodiment, when the food and drink composition of the present invention is ingested for the purpose of obtaining an anti-inflammatory effect, the intake amount may be an amount that can obtain an inflammation suppressing effect, and may be appropriately set according to the subject's body weight, etc.

[0041] In one embodiment, when the food and drink composition of the present invention is ingested by a human (adult), the intake amount of Pep1 and / or a salt thereof is preferably 0.001 mg or more, more preferably 0.01 mg or more, and preferably 200 mg or less, more preferably 100 mg or less per 60 kg body weight per day, calculated as Pep1. In one embodiment, the intake amount of Pep1 and / or a salt thereof is preferably 0.001 to 200 mg, more preferably 0.01 to 100 mg, calculated as Pep1, per 60 kg body weight per day for a human (adult).

[0042] In one embodiment, when the food and drink composition of the present invention is ingested by a human (adult), the intake amount of the type II collagen hydrolysate of chicken cartilage (converted to solid content) is preferably 0.01 mg or more, more preferably 0.1 mg or more, and preferably 4000 mg or less, more preferably 3000 mg or less per 60 kg body weight per day. In one embodiment, the intake amount of the type II collagen hydrolysate of chicken cartilage for a human (adult) is preferably 0.01 to 4000 mg, more preferably 0.1 to 3000 mg per 60 kg body weight per day. As used herein, an intake of type 2 collagen hydrolysate of chicken cartilage includes Pep1 and / or a salt thereof.

[0043] In one embodiment, when the food and drink composition of the present invention is ingested by a human (adult), the intake amount of the chicken extract (in terms of solid content) is preferably 0.1 mg or more, more preferably 1 mg or more, and preferably 15000 mg or less, more preferably 13000 mg or less per 60 kg body weight per day. In one embodiment, the intake amount of the chicken extract (in terms of solid content) is preferably 0.1 to 15000 mg, more preferably 1 to 13000 mg, per 60 kg body weight per day for a human (adult). The intake amount of the chicken extract includes carnosine, anserine, and salts thereof.

[0044] In one embodiment, when the food and drink composition of the present invention is ingested by a human (adult), the total intake of carnosine, anserine and their salts is preferably 0.001 mg or more, more preferably 0.01 mg or more, and preferably 500 mg or less, more preferably 400 mg or less per 60 kg body weight per day in terms of carnosine and anserine. In one embodiment, when carnosine and anserine are ingested by a human (adult), the total intake of carnosine, anserine and their salts is preferably 0.001 to 500 mg, more preferably 0.01 to 400 mg, per 60 kg body weight per day in terms of carnosine and anserine.

[0045] In one aspect, it is preferable that the above-mentioned amount of the type II collagen hydrolysate of chicken cartilage containing Pep1 and / or a salt thereof and the chicken extract is ingested once or more times a day, for example, once or several times a day (for example, 2 to 3 times). In one aspect, it is preferable that the above-mentioned amount of the type II collagen hydrolysate of chicken cartilage containing Pep1 and / or a salt thereof and the above-mentioned amount of chicken extract are ingested by a human. In one aspect, the composition of the present invention can be used to have a human ingest the above-mentioned amount of the type II collagen hydrolysate of chicken cartilage containing Pep1 and / or a salt thereof and the above-mentioned amount of chicken extract per 60 kg of body weight per day.

[0046] In one aspect, when the food and beverage composition of the present invention is ingested for the purpose of obtaining an anti-inflammatory effect, it is preferable to ingest a type II collagen hydrolysate of chicken cartilage containing the above-mentioned amount of Pep1 and / or a salt thereof and the above-mentioned amount of chicken extract.

[0047] The food and drink composition of the present invention suppresses the production of cytokines such as macrophage inflammatory protein-1 (MIP-1), monocyte chemotactic protein-1 (MCP-1), interleukin-6 (IL-6), interleukin-7 (IL-7), interleukin-8 (IL-8), interleukin-9 (IL-9), interleukin-12 (IL-12), and RANTES (regulated on activation, normal T cell expressed and secreted). The food and drink composition of the present invention is highly effective in suppressing the production of MIP-1β, MCP-1, IL-6, IL-7, IL-8, IL-9, IL-12, and RANTES, among others. By suppressing the production of the above cytokines, inflammation in the body can be suppressed.

[0048] The food and drink composition of the present invention can be used for the prevention or improvement of inflammatory conditions or diseases. Inflammatory conditions or diseases include conditions or diseases caused by inflammation or conditions or diseases accompanied by inflammation. Examples of such conditions or diseases include collagen diseases such as arthritis and rheumatoid arthritis, inflammatory bowel disease, osteoarthritis, tendonitis, sciatica, herniated disc, stenosis, myelopathy, lower back pain, facet joint pain, carpal tunnel syndrome, tarsal tunnel syndrome, lumbar postoperative pain syndrome, AIDS, arteriosclerosis, asthma, arthritis, diabetes, hepatitis, stroke, dementia, muscle wasting, viral infection, skin aging including photoaging, cancer, aging, allergic diseases, Parkinson's disease, cerebral infarction, cataracts, epilepsy, and spinal cord injury. , retinopathy of prematurity, nephropathy, peptic ulcer, pancreatitis, ulcerative colitis, myocardial infarction, adult respiratory distress syndrome, emphysema, vasculitis, edema, diabetic complications, UV damage, altitude sickness, porphyrinemia, burns, frostbite, contact dermatitis, shock, multiple organ failure, DIC, fatigue, sarcopenia (muscle weakness), mitochondrial dysfunction, Alzheimer's disease, psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, and systemic lupus erythematosus (lupus). The food and drink composition of the present invention is preferably used for the prevention or improvement of these diseases. In particular, it is preferably used for the prevention or improvement of osteoarthritis, rheumatoid arthritis, and psoriatic arthritis. As used herein, prevention of a condition or disease includes preventing onset, delaying onset, reducing the incidence, reducing the risk of onset, etc. Amelioration of a condition or disease includes recovering a subject from a condition or disease, alleviating the symptoms of a condition or disease, ameliorating the symptoms of a condition or disease, delaying or preventing the progression of a condition or disease, etc.

[0049] The subject to which the food and drink composition of the present invention is ingested (also referred to as the administration subject) is not particularly limited, and is preferably a human or a non-human mammal, more preferably a human. In one embodiment, the subject of administration includes a subject who needs or desires the suppression of inflammation. Such subjects include, for example, a subject who needs or desires the prevention or improvement of inflammation, and a subject who needs or desires the prevention or improvement of the above-mentioned inflammatory conditions or diseases. In one embodiment, the subject of administration in the present invention includes middle-aged and elderly people. The food and drink composition of the present invention can also be used for healthy individuals, for example, for the purpose of preventing conditions that can be prevented or improved by suppressing inflammation.

[0050] The food and drink composition of the present invention may be labeled with a function exhibited by suppressing inflammation. Such a label is also called a functional label, and the labeling content is not particularly limited. Examples of such labels include "relieve joint pain," "reduce joint pain," "condition the knee," "keep the knee healthy," "improve joint health," "improve joint movement," and the like, or labels or functional labels that can be considered equivalent thereto. In one aspect of the present invention, the food and drink composition of the present invention is preferably a food and drink with the above-mentioned label attached, and more preferably a beverage. The above-mentioned label may be a label indicating that the food and drink composition of the present invention is used to obtain the above-mentioned function. The label may be attached to the food and drink composition itself, or to the container or packaging of the food and drink composition.

[0051] <Bone resorption inhibiting composition> In another embodiment, the food and drink composition of the present invention can be used to suppress the bone resorption activity of osteoclasts. The food and drink composition of the present invention can be used as a composition for inhibiting bone resorption. The present invention also includes a composition for inhibiting bone resorption that contains Pep1 and / or a salt thereof as an active ingredient.

[0052] In order to obtain the bone resorption inhibitory effect targeted in the present invention, a type II collagen hydrolysate of chicken cartilage containing Pep1 and / or a salt thereof is blended into a food and drink composition, as in the above-mentioned anti-inflammatory composition. The type II collagen hydrolysate of chicken cartilage containing Pep1 and / or a salt thereof may be used as is, or may be blended in the form of a concentrate, a dried powder, or a product with a high degree of purification as described above, so long as it does not impair the effects of the present invention. The additives and the like that can be used are the same as those described above.

[0053] When the food and drink composition of the present invention is used to suppress bone resorption activity, the intake amount is not particularly limited. The intake amount of the food and drink composition of the present invention may be an amount that can obtain the effect of suppressing bone resorption activity, and may be appropriately set according to the body weight of the subject, etc.

[0054] When the food and drink composition of the present invention is ingested by a human (adult) for the purpose of suppressing bone resorption activity, the amount and frequency of ingestion of Pep1 and / or a salt thereof, and the type II collagen hydrolysate of chicken cartilage can be set to the same amount and frequency as those of the above-mentioned anti-inflammatory composition. In one aspect, it is preferable for a human to ingest the type II collagen hydrolysate of chicken cartilage containing the above amount of Pep1 and / or a salt thereof. In one aspect, the food and drink composition of the present invention can be used to have a human (body weight 60 kg) ingest the type II collagen hydrolysate of chicken cartilage containing the above amount of Pep1 per day.

[0055] In one aspect, when the food and beverage composition of the present invention is ingested for the purpose of obtaining a bone resorption inhibitory effect, it is preferable to ingest a type II collagen hydrolysate of chicken cartilage containing the above-mentioned amount of Pep1 and / or a salt thereof.

[0056] The food and drink composition of the present invention inhibits the bone resorption activity of osteoclasts. By inhibiting the bone resorption activity of osteoclasts, bone mass loss can be inhibited or ameliorated. Inhibition of bone mass loss includes maintaining bone mass and slowing or stopping the progression of bone mass loss. Amelioration of bone mass loss includes restoring bone mass, increasing bone mass, reducing the degree of bone mass loss, etc.

[0057] The food and drink composition of the present invention can be used for preventing or improving conditions or diseases associated with bone loss. Examples of such conditions or diseases include osteoporosis, osteopenia, etc. The food and drink composition of the present invention is preferably used for preventing or improving these diseases.

[0058] In one embodiment, the subject of administration includes a subject who needs or desires to inhibit bone resorption activity. Such a subject includes, for example, a subject who needs or desires to prevent or improve a condition or disease associated with bone loss. In one embodiment, the subject of administration in the present invention includes middle-aged and elderly people. The composition of the present invention can also be used in healthy individuals for the purpose of preventing a condition associated with bone loss that can be prevented or improved by inhibiting bone resorption activity.

[0059] The food and drink composition of the present invention may be labeled with a functional claim indicating the effect exerted by suppressing bone resorption activity. Examples of such claims include "increasing bone density," "replenishing bone mass," "maintaining bone health," "preventing bone loss," and the like, or claims or functional claims that can be considered equivalent thereto. In one aspect of the present invention, the food and drink composition of the present invention is preferably a food and drink with the above-mentioned label attached, and more preferably a beverage. The above-mentioned label may be a label indicating that the food and drink composition of the present invention is used to obtain the above-mentioned function. The label may be attached to the food and drink composition itself, or to the container or packaging of the food and drink composition.

[0060] <Manufacturing method> The present invention also relates to a method for producing a food or beverage composition, which includes a step of blending a peptide (Pep1) consisting of the amino acid sequence represented by Gly-Pro-Glu-Gly-Ala-Pro-Gly-Lys-Asp (sequence number 1) and / or a salt thereof. In the blending step, Pep1 and / or a salt thereof can be blended alone into the food and drink composition, but it is preferable to produce the food and drink composition by blending a type II collagen hydrolysate of chicken cartilage containing Pep1 and / or a salt thereof. In this case, for example, the hydrolysate obtained by hydrolyzing type II collagen of chicken cartilage with an enzyme or the like can be blended directly into the food and drink composition. In addition, as described above, a concentrate, a dried powder, or a product with a high degree of purification may be blended, as long as it does not impair the effects of the present invention.

[0061] The production method of the present invention preferably further comprises the step of blending an animal extract and / or a plant extract. In the manufacturing method of the present invention, the order of mixing the raw materials is not particularly limited. For example, Pep1 and / or a salt thereof, or a type II collagen hydrolysate of chicken cartilage containing Pep1 and / or a salt thereof may be first put into a container or the like, and then an animal extract and / or a plant extract may be added. Alternatively, an animal extract and / or a plant extract may be first put into a container or the like, and then Pep1 and / or a salt thereof, or a type II collagen hydrolysate of chicken cartilage containing Pep1 and / or a salt thereof may be added. Of the above animal extracts and plant extracts, the extract is preferably an animal extract, more preferably an avian extract, even more preferably an extract of poultry, and particularly preferably a chicken extract. In the production method of the present invention, the preferred embodiment of the type II collagen hydrolysate of chicken cartilage is the same as that described above, and the preferred embodiment of the chicken extract is the same as that described above. In the production method of the present invention, it is preferable that the chicken extract contains one or more of carnosine and / or anserine and / or salts thereof.

[0062] In the production method of the present invention, chicken extract, whether commercially available or produced by hot water extraction, can be directly blended with Pep1 and / or its salt, or type II collagen hydrolysate of chicken cartilage containing Pep1 and / or its salt. When chicken extract is in the form of a concentrate, dry powder, or a purified product thereof, it may be diluted, dissolved, etc. with a liquid such as water, ethanol, or a mixture thereof, and then blended with Pep1 and / or its salt, type II collagen hydrolysate of chicken cartilage, etc. Similarly, when type II collagen hydrolysate of chicken cartilage containing Pep1 and / or its salt is in the form of a concentrate, dry powder, or a purified product thereof, it may be diluted, dissolved, etc. with the above-mentioned liquid before use. Alternatively, the raw materials may be blended without dilution, dissolution, etc. in advance, and then diluted, dissolved, etc. by adding a liquid.

[0063] The food and beverage compositions produced by the manufacturing method of the present invention can contain Pep1 and / or a salt thereof, type II collagen hydrolysate from chicken cartilage, and chicken extract, as well as the same additives as those mentioned above.

[0064] The present invention also relates to use of a type II collagen hydrolysate containing a peptide (Pep1) consisting of the amino acid sequence represented by Gly-Pro-Glu-Gly-Ala-Pro-Gly-Lys-Asp (SEQ ID NO: 1) and / or a salt thereof for the production of an anti-inflammatory composition. The anti-inflammatory composition may be the same as the food and drink composition containing the type II collagen hydrolysate of chicken cartilage containing Pep1 and / or a salt thereof. The chicken extract and other additives may be the same as those described above.

[0065] The present invention also relates to the use of a peptide (Pep1) consisting of the amino acid sequence represented by Gly-Pro-Glu-Gly-Ala-Pro-Gly-Lys-Asp (sequence number 1) and / or a salt thereof for the production of a composition for inhibiting bone resorption. The bone resorption inhibiting composition may be the same as the food and drink composition containing Pep1 and / or its salt. Pep1 and / or its salt may be used in the form of a type II collagen hydrolysate of chicken cartilage containing Pep1 and / or its salt. Other additives may be the same as those described above.

[0066] The present invention also relates to a composition for inhibiting bone resorption, which contains chicken extract as an active ingredient. The composition for inhibiting bone resorption of the present invention has the effect of inhibiting bone resorption by osteoclasts. The composition of the present invention contains chicken extract as an active ingredient and is therefore capable of exerting a bone resorption inhibitory effect.

[0067] The chicken extract and its preferred embodiments are the same as those described above. The composition may contain the above-mentioned additives as desired. The bone resorption inhibiting composition of the present invention may further contain the above-mentioned chicken cartilage type II collagen hydrolysate.

[0068] In one embodiment, the content of chicken extract (in terms of solid content) in the bone resorption inhibiting composition of the present invention is, for example, preferably 0.1% by weight or more, more preferably 0.5% by weight or more, and preferably 99% by weight or less, more preferably 90% by weight or less. In one embodiment, the content of chicken extract (in terms of solid content) in the composition is, for example, preferably 0.1 to 99% by weight, more preferably 0.5 to 90% by weight.

[0069] The bone resorption inhibiting composition of the present invention preferably contains one or more of carnosine and / or anserine and / or their salts. In one aspect, the content of carnosine and / or anserine and / or their salts in the composition of the present invention is, for example, preferably 0.00001 wt% or more, more preferably 0.0001 wt% or more, and preferably 10 wt% or less, more preferably 1 wt% or less, in terms of carnosine. In one aspect, the content of carnosine in the composition is, for example, preferably 0.00001 to 10 wt%, more preferably 0.0001 to 1 wt%.

[0070] In one embodiment, the content of anserine and / or a salt thereof in the composition for inhibiting bone resorption of the present invention is, for example, preferably 0.00001% by weight or more, more preferably 0.0001% by weight or more, and preferably 10% by weight or less, more preferably 1% by weight or less, calculated as anserine. In one embodiment, the content of anserine in the composition is, for example, preferably 0.00001 to 10% by weight, more preferably 0.0001 to 1% by weight.

[0071] The intake amount of the composition for inhibiting bone resorption of the present invention is not particularly limited. The intake amount of the composition of the present invention may be an amount that can obtain the effect of inhibiting bone resorption by mature osteoclasts, and may be appropriately set depending on the body weight of the subject, etc.

[0072] In one embodiment, when the bone resorption inhibiting composition of the present invention is ingested by a human (adult), the intake amount of the chicken extract (in terms of solid content) is preferably 0.1 mg or more, more preferably 1 mg or more, and preferably 15000 mg or less, more preferably 13000 mg or less per 60 kg body weight per day. In one embodiment, the intake amount of the chicken extract (in terms of solid content) is preferably 0.1 to 15000 mg, more preferably 1 to 13000 mg, per 60 kg body weight per day for a human (adult). The intake amount of the chicken extract contains carnosine and anserine.

[0073] In one embodiment, when the bone resorption inhibiting composition of the present invention is ingested by a human (adult), the total intake of carnosine, anserine and their salts is preferably 0.001 mg or more, more preferably 0.01 mg or more, and preferably 500 mg or less, more preferably 400 mg or less per 60 kg body weight per day, calculated as carnosine and anserine. In one embodiment, the total intake of carnosine, anserine and their salts is preferably 0.001 to 500 mg, more preferably 0.01 to 400 mg, calculated as carnosine and anserine, per 60 kg body weight per day for a human (adult).

[0074] In one aspect, it is preferable to ingest the above amount of chicken extract once or more per day, for example, once or several times (e.g., 2 to 3 times) a day. In one aspect, it is preferable to let a human ingest the above amount of chicken extract. In one aspect, the composition of the present invention can be used to let a human (weight 60 kg) ingest the above amount of chicken extract per day. The preferable administration target of the composition for suppressing bone resorption is the same as above.

[0075] The present invention also relates to the use of chicken extract for producing a composition for suppressing bone resorption. Examples of the composition for suppressing bone resorption include compositions similar to the food and drink compositions containing the above-mentioned chicken extract. Also, the same chicken extract and other additives as those described above can be used.

Examples

[0076] Hereinafter, the present invention will be specifically described by way of examples. Note that the present invention is not limited only to these examples.

[0077] 1. Inhibitory effect on inflammation The raw materials, reagents, etc. used in the following examples and comparative examples are shown below. <Preparation of type II collagen hydrolysate of chicken cartilage> FIG. 1 shows a flow briefly explaining the method for preparing HCII. First, frozen chicken cartilage was thawed with water at 40°C and washed with water at 40°C (for 1 hour). Next, the washing water was discarded, and new water was put into a 1200 L pot so that the amount was three times that of the chicken cartilage. The water was heated to the temperature optimal for enzymatic treatment, and the washed chicken cartilage was immersed therein, and enzymatic treatment was performed for several hours. After the enzymatic treatment, the pot containing the chicken cartilage was heated to 90°C or higher and held at 90°C or higher for 30 minutes to inactivate the enzyme used in the previous enzymatic treatment. The obtained mixture (liquid and chicken cartilage after enzymatic treatment) was filtered. The obtained liquid was concentrated. Finally, the obtained concentrated solution was spray-dried at 200°C to prepare HCII powder.

[0078] <Measurement of molecular weight of HCII powder> The molecular weight distribution of the obtained HCII was measured by the Eurofins HPAEC-PAD method. The molecular weight distribution of the obtained HCII is shown in Table 1 below. The weight average molecular weight of HCII calculated by the usual method used in this field was 4582.

[0079]

Table 1

[0080] <Fractionation of HCII fractions and identification of peptides> (Materials and methods for HCII fractionation and bioactivity identification) (Materials) Formic acid was purchased from Tokyo Chemical Industry Co., Ltd. Ultra-pure water was obtained from a Merck Milli-Q water purification system. The synthetic peptide GPEGAPGKD was obtained from GenScript.

[0081] (Preparative gel permeation chromatography (GPC)) Fractionation of HCII was carried out using a preparative VERITY271 HPLC system (manufactured by Gilson). HCII was dissolved in ultra-pure water to prepare a 10 mg / mL (w / v) solution. After centrifugation at 14000 rpm for 5 minutes, an aliquot (1000 μL) was injected into a preparative GPC column (BioSep 5 μm SEC-s2000 145 Å LC column 300×21.2 mm (manufactured by Phenomenex)) attached to a guard column (SecurityGuard PREP Cartridge C12 15×21.2 mm ID (manufactured by Phenomenex)), and isocratic elution was performed with eluent A (ultra-pure water: formic acid = 100:0.1 (v / v)) at a flow rate of 5 mL / min for 30 minutes. The chromatogram was observed at 214 nm. Fractions were collected every 0.5 min between 8 and 28 min using a GX series fraction collector (Gilson), and the resulting 40 individual fractions were then pooled into seven fractions, P1 to P7 (P1: 8.5-12.0 min, P2: 12.0-13.5 min, P3: 13.5-14.5 min, P4: 14.5-16.0 min, P5: 16.0-17.5 min, P6: 17.5-19.0 min, P7: 19.0-27.5 min). The pooled fractions were evaporated to dryness using a freeze dryer (ScanVac), and the dried samples were stored at -20 °C until further use.

[0082] The molecular weights of the fractions obtained above are shown in Table 2. In Table 2, "Mw" and "Mp" indicate the weight average molecular weight and the peak molecular weight, respectively. As shown in Table 2, fraction 1 (P1) and fraction 2 (P2) were composed of molecules with average molecular weights of 1359 (P1) and 1092 (P2), respectively. The molecular weight of the HCII fraction was measured by HPLC gel filtration under the following conditions. Equipment: Agilent 1100 series Detection: UV214nm Flow rate: 1mL / min Mobile phase: Isocratic 0.1 mM sodium phosphate buffer at pH 6.8 Run Time: 20 minutes Column: Biosep TM 5μm SEC-s2000 145Å LC column 300×7.8mm

[0083] [Table 2]

[0084] (In-silico search for peptides containing GPEGAPGKD) Fractions P1 to P7 were subjected to LC-MS analysis on a TripleTOF5600 (AB Sciex) coupled to an Agilent HPLC 1290 series using a Duo Spray Turbo V ion source and gas generator (Peak Scientific). The major components were separated using UHPLC Guard Zorbax EclipsePlusC18 2.1×5 mm 1.8 μm (Agilent) and eluted with eluent A (ultrapure water:formic acid = 100:0.1 (v / v)) and eluent B (acetonitrile:formic acid = 100:0.1 (v / v)) with the following linear gradient: 0-0.5 min: eluent A 100%; 0.5-7.5 min: eluent A 100-65%; 7.5-10.0 min: eluent A 65-0%; 10.0-13.0 min: eluent A 0%; 13.0-13.1 min: eluent A 0-100%; 13.1-15.0 min: eluent A 100%. The experiment was performed in the position mode of the Independent Data Acquisition (IDA) method, and the collision energy (CE) and de-clustering potential (DP) of the MS were optimized at 10.0 V and 80 V, respectively. Analysis was performed with PeakView (AB Sciex). The mass spectrometry data was then analyzed and searched using ProteinPilot (AB Sciex) attached to the Uniprot KBfasta file with the keyword gallus gallus. The data was further processed with a candidate list of interest and confirmed with peptides purchased from Genscript.

[0085] (Detection and quantification of peptide markers by LC-MS analysis) Detection and quantification of peptide GPEGAPGKD was performed by LC-MS. LC-MS analysis was performed on a TripleTOF5600 (AB Sciex) coupled to an Agilent HPLC1290 series using a Duo Spray Turbo V ion source and gas generator (Peak Scientific). The mass spectrometer used electrospray ionization and multiple reaction monitoring (MRM) in positive ion mode at unit mass resolution. The parameters were as follows: collision energy spread (CES): 10; ion ejection delay (IRD): 67; ion ejection width (IRW): 25; ion source gas: 40; curtain gas (CUR): 30; temperature: 500.0; ion spray voltage floating (ISVF): 5500). MS compound-dependent parameter settings such as declustering potential (DP) and collision energy (CE) were optimized for each peptide. Analyst 1.5.2 (AB Sciex) was used for instrument control, data acquisition, and data processing.

[0086] GPEGAPGKD was reconstituted in ultrapure water and injected onto a ZIC-HILIC 3.5 μm 100 Å 2.1 × 50 mm column (Merck) containing a SeQuant ZIR-HILIC Guard Fitting PEEK coated 14 × 1 mm column (Merck) and eluted with eluent A (ultrapure water:formic acid = 100:0.1 (v / v)) and eluent B (acetonitrile:formic acid = 100:0.1 (v / v)) using the following linear gradient: 0-0.5 min: eluent A 10%; 0.5-5.5 min: eluent A 10-45%; 5.5-10 min: eluent A 45-70%; 10-12 min: eluent A 70-80%; 12-13.5 min: eluent A 80-10%; 13.5-15 min: eluent A 10%. The injection volume was 10 μL, the flow rate was 300 μL / min, and the UV absorbance of the eluent was monitored at 214 nm. The collision energy (CE) and declustering potential (DP) of the MS were optimized as 20 V and 85 V, respectively. GPEGAPGKD was detected at m / z 414.2 / 641.3 Th using Q1 / Q3 ion transitions at a retention time of 7.1 min as a quantitative ion and a confirmatory ion. A calibration curve was prepared with 15.25, 31.5, 62.5, 125, and 250 ng / mL of standard GPEGAPGKD. A 500 μg / mL solution of HCII was reconstituted as a working solution. Quantification of GPEGAPGKD in HCII and its GPC fractions was performed using MultiQuant (AB Sciex). Pep1 was contained in fractions P1 and P2 of HCII, and the content of Pep1 relative to HCII (1 g) was 53.7±0.007 μg / g.

[0087] <Quantitative Analysis of Carnosine and Anserine> The quantitative determination of carnosine and anserine in chicken extract was carried out by HPLC under the following conditions. A standard stock solution of carnosine was prepared by dissolving carnosine powder in deionized water to give a carnosine concentration of 2.50 mg / ml, and a standard stock solution of anserine was prepared by dissolving L-anserine nitrate powder in deionized water to give an L-anserine concentration of 3.96 mg / ml. The weight of L-anserine was calculated using the following formula: L-anserine (g) = 0.792 × L-anserine nitrate (g) <HPLC analysis conditions> Apparatus: High-performance liquid chromatography system with ultraviolet detector (Agilent 1100 (manufactured by Agilent)) Column: Zorbax 300-SCX 4.6 mm ID × 250 mm (manufactured by Agilent) Mobile phase: 50 mM potassium dihydrogen phosphate Flow rate: 1.0 mL / min Flow channels: Channel A (50 mM potassium dihydrogen phosphate), Channel B (acetonitrile), Channel D (deionized water) UV detection wavelength: 210 nm Sample injection volume: 10 μL

[0088] <Method for evaluating anti-inflammatory activity> In Examples 1 to 3, the inhibitory effect on the production of inflammatory markers was evaluated by the following method. (Raw materials and reagents) Chicken extract (CE): Brand’s Essence of Chicken (Suntory Food Asia, content of carnosine in 1 ml: 0.94 mg / ml, content of anserine in 1 ml: 1.9 mg / ml) Chondrocyte medium (CM), fetal bovine serum (FBS), chondrocyte growth supplement (CGS), and penicillin / streptomycin (P / S): manufactured by ScienCell Research Laboratories IL-1β: manufactured by R&D Systems Poly-L-lysine (PLL)-coated 96-well plate (manufactured by Corning)

[0089] <Cell culture and pretreatment> Human chondrocytes (HC-a, ScienCell Research Laboratories) were isolated from human articular cartilage and stored in CM supplemented with 5% FBS, 1% CGS, and 1% P / S. Cells were seeded at a cell density of 4000 cells / well in PLL-coated 96-well plates and cultured overnight at 37°C in a humidified gas chamber containing 5% CO2. Chondrocytes were washed once with PBS and pretreated for 24 hours with various concentrations of HCII, chicken extract (CE), a combination of HCII and CE, a fraction fractionated from HCII, or GPEGAPGKD, and further treated with 25 ng / mL IL-1β for 24 hours. Cells were centrifuged at 1100g for 5 minutes, and the supernatant was used for cytokine analysis. For comparison, cells were prepared that were treated with IL-1β without pretreatment with HCII, CE, a fraction fractionated from HCII, or GPEGAPGKD (IL-1β-treated cells).

[0090] <Multiple cytokine analysis> The cytokines in the medium were analyzed using Pro-Human Cytokine Multiplex Assays (Bio-Rad Laboratories), which included 27 multiplex assays: IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8 (CXCL8), IL-9, IL-10, IL-12, IL-13, IL-15, IL-17, eotaxin (CCL11), macrophage colony-stimulating factor (M-CSF), interferon (IFN)-γ, monocyte chemoattractant protein 1 (MCP-1; CCL2), macrophage inflammatory protein-1α (MIP-1α; CCL3), MIP-1β (CCL4), RANTES (regulated on activation, normal T cell expressed and secreted) (CCL5), TNF-α, and vascular endothelial growth factor (VEGF). The multiplex analysis was performed according to the manufacturer's instructions and run on the Luminex xPONENT for MAGPIX platform. Bio-Plex Manager version 6.0 was used for data processing. Cytokine and chemokine concentrations were calculated by reference to standard curves. The sensitivity of the multiplex kit was less than 5 pg / mL.

[0091] <Statistical analysis> Statistical analysis was performed using GraphPad Prism version 5.0 (GraphPad Inc.). All results are expressed as mean ± standard deviation. Statistical analysis was performed by analysis of variance (ANOVA) followed by post-hoc Tukey's multiple comparison test. Data were considered significant when P value was p<0.05.

[0092] <Example 1 and Comparative Examples 1 and 2> To evaluate the effect of HCII and chicken extract (CE) on the inflammatory marker MIP-1β produced by human chondrocytes, four different conditions were compared: cells before treatment (untreated control), IL-1β-treated cells (Comparative Example 1), IL-1β+HCII-treated cells (Example 1), and IL-1β+CE-treated cells (Comparative Example 2). HCII-treated cells and CE-treated cells were pretreated with HCII or CE. In the pretreatment, the HCII concentration was 0.5 mg / ml or 2.5 mg / ml, and the CE concentration was 1.25 mg / ml or 6.25 mg / ml. As shown in Figure 2, 25 ng / mL IL-1β induced inflammation in human chondrocytes and significantly increased the levels of MIP-1β compared to untreated cells (control). Pretreatment of cells with HCII and CE reduced the levels of MIP-1β induced by IL-1β. There was also a dose-dependent effect of HCII and CE on inhibiting the production of MIP-1β. In Figure 2, data are expressed as mean ± SD (n = 3). Unless otherwise indicated, * indicates significant difference relative to IL-1β (IL-1β-treated cells) with p < 0.05, ** indicates significant difference with p < 0.01, and *** indicates significant difference with p < 0.001.

[0093] Example 2: Synergistic effect of combination of HCII and CE To evaluate the synergistic effect of the combination of HCII and CE on the inhibition of the production of the inflammatory marker MIP-1β, pretreatment was performed with HCII alone, CE alone, or a combination of HCII and CE. The HCII concentration during pretreatment was 0.5 mg / ml, and the CE concentration was 1.25 mg / ml. As shown in Figure 3, the combination of HCII 0.5 mg / mL and CE 1.25 mg / mL produced a synergistic effect in reducing inflammation compared to treatment with HCII or CE alone. Data are expressed as mean ± SD (n = 3). Unless otherwise indicated, * indicates significant difference vs. IL-1β (IL-1β-treated cells) with p < 0.05, ** indicates significant difference vs. p < 0.01, and *** indicates significant difference vs. IL-1β (IL-1β-treated cells) with p < 0.001.

[0094] Example 3: Effect of fractions isolated from HCII on regulation of inflammatory markers Among the seven fractions separated from HCII, P1 and P2 were used. As in Example 1, cells were pretreated with IL-1β and HCII, as well as P1 or P2 (HCII, P1, and P2 at concentrations of 5 mg / mL, respectively), and the effects were compared. The results are shown in Figure 4. Data are expressed as mean ± SD (n = 3). Unless otherwise indicated, * indicates significant difference from IL-1β (IL-1β-treated cells) with p < 0.05, ** indicates significant difference with p < 0.01, and *** indicates significant difference with p < 0.001.

[0095] <Example 4 and Comparative Example 3> To evaluate the effect of HCII on the inflammatory markers IL-6, IL-7, IL-9 and IL-12, three different conditions were compared: untreated cells (untreated control), IL-1β-treated cells (Comparative Example 3), and IL-1β+HCII-treated cells (Example 4). HCII-treated cells were pretreated with HCII. In the pretreatment, the concentration of HCII was 0.5 mg / ml or 2.5 mg / ml. As shown in Figure 5, 25 ng / mL IL-1β induced inflammation in human chondrocytes and significantly increased the levels of IL-6, IL-7, IL-9, or IL-12 compared to untreated cells (control). Pretreatment of cells with HCII reduced the levels of IL-1β-induced IL-6, IL-7, IL-9, and IL-12. There was also a dose-dependent effect of HCII on suppressing the production of IL-9 and IL-12. In Figure 5, data are expressed as mean ± SD (n = 3). Unless otherwise indicated, * indicates significant difference vs. IL-1β (IL-1β-treated cells) with p < 0.05, ** indicates significant difference with p < 0.01, and *** indicates significant difference with p < 0.001.

[0096] Example 5: Synergistic effect of the combination of GPEGAPGKD and CE on the inhibition of the production of the inflammatory marker MCP-1 To evaluate the synergistic effect of the combination of GPEGAPGKD and CE on the inhibition of production of the inflammatory marker MCP-1, pretreatment was performed under the conditions of a combination of IL-1β, GPEGAPGKD, and CE, as in Example 1. In the pretreatment, the concentration of GPEGAPGKD was 2.5 mg / ml, and the concentration of CE was 6.25 mg / ml. The results are shown in Figure 6. Data are expressed as mean ± SD (n = 3). Unless otherwise indicated, * indicates significant difference from IL-1β (IL-1β-treated cells) with p < 0.05, ** indicates significant difference with p < 0.01, and *** indicates significant difference with p < 0.001.

[0097] Example 6: Synergistic effect of the combination of GPEGAPGKD and CE on the inhibition of inflammatory marker production To evaluate the synergistic effect of the combination of GPEGAPGKD and CE on the inhibition of production of inflammatory markers IL-6, IL-8, IL-9, MCP-1, MIP-1β, and RANTES, pretreatment was performed under the conditions of a combination of IL-1β, GPEGAPGKD, and CE in the same manner as in Example 1. In the pretreatment, the concentration of GPEGAPGKD was 25 mg / ml, 125 mg / ml, or 250 mg / ml, and the concentration of CE was 6.25 mg / ml. The results are shown in Figure 7-1(a), Figure 7-1(b), Figure 7-1(c), Figure 7-2(d), Figure 7-2(e), and Figure 7-2(f). Data are expressed as mean ± SD (n=3). Unless otherwise indicated, * indicates significant difference from IL-1β (IL-1β-treated cells) with p<0.05, ** indicates significant difference with p<0.01, and *** indicates significant difference with p<0.001.

[0098] 2. Bone resorption inhibitory effect (type II collagen hydrolysate from chicken cartilage) The raw materials, reagents, etc. used in the following examples are shown below. The type II collagen hydrolysate of chicken cartilage used was the same as that prepared and used in the Examples for "1. Inflammation suppression effect" above. OsteoLyse assay kit (human collagen), osteoclast precursors (OCP), OCP Bulletkit containing OCP basal medium, and OCP proliferation medium SingleQuots kit were purchased from Lonza. The OCP growth medium SingleQuots kit contained fetal bovine serum, L-glutamine, penicillin / streptomycin, macrophage colony-stimulating factor, and soluble RANK ligand and was obtained from Lonza. Additionally, the OsteoLyse Assay Kit (Human Collagen) includes a 96-well OsteoLyse plate, a fluorophore releasing reagent, and a 96-well assay plate (black).

[0099] In the following examples, the bone resorption inhibitory effect was evaluated by the following method. Cell culture and treatment Human primary osteoclast precursors (OCP, Cat.#2T-110) were thawed and seeded at 10000 cells / well in 96-well OsteoLyse plates by OsteoLyse Assay Kit (Cat.#PA-1500). Human primary osteoclast precursors were stored in OCP basal medium (Cat.#PT-8201) containing FBS (10%), L-glutamine (2mM), penicillin (100units / ml) / streptomycin (100μg / ml). To complete the differentiation medium for human primary osteoclast precursors, RANK ligand and M-CSF were added to the growth medium at the amounts of 66ng / ml and 33ng / ml, respectively. The precursor cells were cultured at 37℃ in a humidified gas chamber containing 5% CO2 for 7 days to fully differentiate into functionally mature osteoclasts. The morphology of the cells was examined by microscopy to confirm that the precursors were fully differentiated into mature osteoclasts. Undifferentiated cells were kept in growth medium without RANK ligand as a positive control. On day 7, peptide GPEGAPGKD 50 mg / ml, HCII 10 mg / ml, and different fractions isolated from HCII at two concentrations (5 mg / ml and 10 mg / ml) were added to fresh differentiation medium. Cells were cultured for another 3 days at 37°C in a humidified gas chamber containing 5% CO2.

[0100] <Bone resorption inhibition analysis> The bone resorption inhibition assay was performed according to the manufacturer's instructions. The assay directly measured the release of matrix metalloproteinases released into osteoclast resorption lacunae. Fluorophore-derivatized human bone matrix (Europium-conjugated collagen) was coated onto OsteoLyse cell culture plates, and osteoclast resorption activity, reflected by Eu-labeled collagen fragments, was measured using a microplate reader (Tecan, Infinite 200 Pro). Fluorophore-releasing reagent was added to a 96-well plate at 200 uL / well, and 10 μl of cell culture supernatant was transferred and mixed with the fluorophore-releasing reagent. After an initial delay of 400 μs, fluorescence was measured over a period of 400 μs at an excitation wavelength of 340 nm and an emission wavelength of 615 nm. Supernatants were sampled 24, 48, and 72 hours after cell treatment to study the time course.

[0101] <Statistical analysis> Statistical analysis was performed using GraphPad Prism version 5.0 (GraphPad, Inc.). All results are presented as mean ± standard deviation. Statistical analysis was performed by unpaired t-test, and data were considered significant when values ​​were p<0.05.

[0102] <Example 7> Inhibition of bone resorption activity by HCII To evaluate the effect of HCII on the bone resorption activity of mature osteoclasts, four different conditions were compared: undifferentiated cells (positive control), differentiated osteoclasts before treatment (untreated control), and HCII-treated osteoclasts (HCII 6 mg / ml). As shown in Figure 8, mature osteoclasts were treated with HCII at 6 mg / ml for 72 hours. Compared to untreated controls, HCII significantly reduced bone resorption at the 6 mg / ml dose. Data are expressed as mean ± SD (n=3). Unless otherwise indicated, * indicates significant difference vs. untreated control, p<0.05, ** indicates significant difference vs. untreated control, p<0.01, *** indicates significant difference vs. untreated control, p<0.001.

[0103] Example 8: Inhibition of bone resorption activity by seven different HCII fractions HCII was purified and separated into seven fractions (P1-P7) to examine bioactive substances that contribute to the effectiveness of HCII in reducing bone resorption activity. Each fraction was added at 5 mg / mL. Treatment of cells with 5 mg / mL of HCII for 72 hours significantly reduced bone resorption activity (Figure 9). None of the fractions was effective when treated alone at equivalent amounts to HCII. However, when fractions 1 and 2 (P1+P2) were treated in combination, there was a synergistic effect, as shown by the significant reduction in bone resorption activity compared to untreated controls. Data are expressed as mean ± SD (n = 3). Unless otherwise indicated, * indicates significant difference vs. untreated control, p < 0.05, **, p < 0.01, ***, p < 0.001.

[0104] Example 9: Inhibition of bone resorption activity by peptide GPEGAPGKD It was confirmed that the peptide GPEGAPGKD was contained in the combined fraction (P1+P2) of fraction 1 and fraction 2, and its effectiveness was verified. Cells were treated with 5 mg / mL HCII, 5 mg / mL fraction (P1+P2), or 50 mg / mL peptide GPEGAPGKD for 72 hours. As in Example 4, HCII and P1+P2 inhibited the bone resorption activity of osteoclasts at a dose of 5 mg / mL, compared to the untreated control. Peptide GPEGAPGKD showed a significant reduction in bone resorption at 10 times the amount of HCII or fraction P1+fraction P2 (Figure 10). Data are expressed as mean ± SD (n = 3). Unless otherwise indicated, * indicates significant difference vs. untreated control, p < 0.05, **, p < 0.01, ***, p < 0.001.

[0105] HCII dose-dependently inhibited the bone resorption activity of mature osteoclasts. The combination of fraction 1 and fraction 2 significantly hindered the bone resorption activity when compared with untreated cells. The peptide GPEGAPGKD, found in the combined fraction of fraction 1 and fraction 2, also reduced bone resorption. Thus, the peptide GPEGAPGKD may be one of the bioactive substances that partially contributes to the inhibition of bone resorption activity by HCII.

[0106] 3. Bone resorption inhibitory effect (chicken extract) Example 10: Inhibition of bone resorption activity by chicken extract The inhibition of bone resorption activity of mature osteoclasts was examined in the same manner as in Example 7, except that 7.5 mg / ml or 15 mg / ml of chicken extract was used instead of HCII. Treatment of cells with CE at both 7.5 mg / ml and 15 mg / ml showed a significant reduction in bone resorption compared to untreated controls (Figure 11). Unless otherwise indicated, * indicates significant difference vs. untreated control, p<0.05, ** indicates significant difference vs. untreated control, p<0.01, *** indicates significant difference vs. untreated control, p<0.001.

[0107] <Example 11> A randomized, double-blind, four-arm pilot study to examine the effects of HCII and CE on knee pain and bone mass This pilot study was conducted as a single-center, double-blind, randomized, placebo-controlled trial.

[0108] (Subject Enrollment and Randomization) A total of 160 subjects aged 45-75 years were selected using the inclusion and exclusion criteria summarized in Table 3. The subjects were randomly divided into four groups: "Placebo", "Glucosamine", "HCII", and "HCII and CE". Each group included 40 subjects.

[0109] [Table 3]

[0110] (Test product) The "placebo" group received 6.8 g of maltodextrin and 7 mg of xanthan gum. The "glucosamine" group received 1.5 g of glucosamine hydrochloride, which was used as a positive control. The "HCII" group received BRAND Collagen Hydrolysate (Suntory Food Asia), a chicken sternal cartilage hydrolyzate extract consisting of a natural substrate of type II collagen hydrolysate (HCII), low molecular weight chondroitin sulfate, and hyaluronic acid (HA). This product contains HCII with the peptide GPEGAPGKD. Each 68 mL bottle contains 2 g of HCII, providing a natural composition consisting of HCII (66.5%), depolymerized chondroitin sulfate (18%), and HA (11%). The remaining 4.5% is made up of uncharacterized components of sternal cartilage. The "HCII and CE" group consumed a mixture of 70 g (5-6 g dry weight) of Brand's Essence of Chicken (BEC) and 2 g of HCII in a 68 mL bottle. All test products were prepared as liquid products in glass bottles, with isocaloric content, identical appearance, and comparable flavor and texture. Participants consumed the test products once daily in the morning after a meal. Concomitant medications or supplements were permitted to continue if they were deemed not to affect the study results. Painkillers or analgesics were permitted as rescue medications under prescription. Analgesic treatment-day coverage (PDC) was calculated based on the records in the "Concomitant Analgesic Use" column and was defined as the ratio of analgesic treatment-day coverage to the total number of days between visits. All medical treatments and dietary supplements supporting joint, bone, and muscle health, such as hormone therapy (growth hormone, progesterone, estrogen, testosterone), calcium, vitamin D, or supplements rich in amino acids, peptides, proteins, omega-3, omega-6, glucosamine, or chondroitin, were prohibited during the study.

[0111] (procedure) In this study, a screening visit (28 days before the baseline visit) was conducted first, followed by a baseline visit (the baseline visit was on day 0, but the screening visit and baseline visit could be on the same day), and three follow-up visits (weeks 8, 16, and 24). Subjects were screened 28 days before day 0 to day 0 to determine eligibility for the study. From the day after the baseline visit, subjects took the test substance for 168 consecutive days (24 weeks). For 168 consecutive days (24 weeks), subjects took one bottle per day in the morning (after a meal). Compliance was recorded in a diary card. Visual analog scale (VAS) for knee pain was scored on days 0, 7, and 14 after intake. Bone mass assessments were performed at baseline (day 0) and at week 24 only. During the study, subjects were encouraged to perform resistance training at home twice a week for 30 minutes (not compulsory) according to the training schedule. Training was recorded on a diary card, and dietary intake for the week prior to the visit was recorded using a dietary questionnaire.

[0112] (Processing Compliance) Compliance with study product intake was confirmed by collection of unused medication and by subjects' daily intake records. Compliance was defined as the percentage of allocated doses actually taken over the number of days between visits. An intake rate of 70% was considered compliant.

[0113] (Exercise Program) All subjects were encouraged to perform resistance training at home for 30 minutes twice a week, according to the training manual provided at the baseline visit. Compliance with the training program was recorded on a diary card and calculated using the following formula:

[0114]

number

[0115] Compliance rates of ≥50% were considered compliant.

[0116] (Visual Analogue Scale (VAS) for Knee Pain) The visual analog scale (VAS) was scored from 0 to 100 mm, with 0 indicating no pain and 100 indicating the worst pain ever. On days 0, 7, and 14 after ingestion, subjects were asked to identify the level of pain they felt. Pain level was indicated by drawing a line on the scale and indicating the location along the solid line.

[0117] (Bone mass evaluation) Dual-energy x-ray absorptiometry (DXA) was performed at baseline (day 0) and at week 24 to assess bone mass (BM) of the left hip.

[0118] (Tolerability and safety) Spontaneously reported adverse events were recorded during the study. Vital signs were monitored at every visit. Serum and urine samples were collected from all participants at every visit during the study to assess the safety of the study drug.

[0119] (statistical analysis) Per-protocol statistical analyses were performed according to an a priori statistical analysis plan. Randomized subjects with a compliance rate of ≥70% were included in the per-protocol analysis. Analysis of safety parameters was performed in subjects who consumed ≥28 bottles of the study product. Dichotomous variables were reported as percentages, and continuous variables were reported as means and SDs. Chi-square tests were used to compare categorical variables, and Kruskal-Wallis tests were used to compare between-group differences in continuous variables. For continuous primary and secondary outcomes, repeated measures analysis of variance (ANOVA) was performed with intake by visit interaction as a fixed effect factor, using a mixed-effects model used to test for mean differences in change between study groups. All results were considered statistically significant if the corresponding p-value was less than 0.05. If the intake by visit interaction term was significant, post-hoc pairwise comparisons between treatment groups were performed and adjusted p-values ​​were reported. Variables expected to affect the outcomes were included in the model as factors. Analysis of joint health included sex and sex by visit interaction term as factors. Analysis of bone health included sex and resistance training compliance and their respective interaction terms as factors. In addition, subgroup analyses were performed for subjects whose resistance training sessions were below the 10th percentile for the entire training period. Analyses were performed by an independent statistician using SAS version 9.4 (Cary, NC, USA).

[0120] <Result> (Baseline characteristics and treatment compliance) A total of 160 subjects were enrolled, and 151 subjects completed the study and were included in the statistical analysis (PP). Nine subjects dropped out, but there was no significant difference in the number of dropouts between the groups. The dropouts were not related to side effects from taking the test product or placebo. No adverse events were observed. No clinically significant changes were observed in serum biochemical markers and urine tests. Overall, there were no statistical differences in compliance rates among all four groups (Table 4). To assess data homogeneity, all parameters were compared among the four arms. There were no statistically significant differences between the study groups at baseline (Table 4).

[0121] [Table 4]

[0122] (Changes in VAS knee pain scores) After 14 days of intake, pairwise comparisons of the HCII and placebo groups showed a statistically significant difference in pain (p=0.021) in the HCII group compared to the placebo group, as measured by VAS pain scores. Compared to pain scores on day 0, the HCII group showed a decrease of -11.1% from baseline on day 7 and -25% on day 14 (Figure 12(a), Table 5). In fact, the placebo group showed a tendency for pain to increase over the 14 days, with pain scores increasing from day 0 by 33.3% on day 7 and 13.3% on day 14. Furthermore, in a subgroup analysis of subjects whose resistance training frequency was less than the 10th percentile throughout the entire period, the placebo group had a significantly increased pain score compared to the HCII group, by 200% from baseline on day 14 and by 8.7% from day 0 (Figure 12(b) and Table 6). In Tables 5 and 6, "P value ($)" indicates the p value between groups, "(a)" and "(k)" indicate the method used to determine the p value ((a) = one-way analysis of variance, (k) = Kruskal-Wallis test), "*" indicates statistical significance, and "95% CI" indicates the 95% confidence interval. In Figs. 12(a), 12(b) and 13 described below, the two numerical values ​​in parentheses for each data are "mean - standard deviation" and "mean + standard deviation."

[0123] [Table 5]

[0124] [Table 6]

[0125] (Changes in bone mass) After 24 weeks of intake, there was no significant difference in bone mass change between either of the two groups. However, in a subgroup analysis of subjects whose resistance training frequency was below the 10th percentile throughout the entire period, the HCII+CE combined intake group had a significant increase in left hip bone mass of 7.4% from day 0 compared to the placebo intake group at 24 weeks (intake period: p=0.009) (p=0.01) (see Figure 13, Table 7). In Table 7, "P value ($)" indicates the p value between groups, "(a)" indicates the method for determining the p value ((a) = one-way analysis of variance), "*" indicates statistical significance, and "95% CI" indicates the 95% confidence interval.

[0126] [Table 7]

[0127] (Conclusion) In conclusion, HCII was found to be well tolerated and to provide rapid and significant symptom relief to patients suffering from osteoarthritis pain. Ingestion of 2 g HCII significantly reduced knee joint pain in just 14 days compared to placebo. Meanwhile, the combination of HCII and CE significantly increased bone mass in the left hip joint in subjects who underwent minimal resistance training. In vitro studies suggest that the mechanism of action is an improvement in the course of the underlying disease, in particular the inhibition of bone resorption and the inhibition of inflammation resulting in localized pain sensation. HCII and the combination of HCII and CE may be a safe and effective complement to current medical and dietary options in the management of OA symptoms. [Industrial Applicability]

[0128] The present invention provides a novel food and beverage composition comprising a peptide and / or a salt thereof. The food and beverage composition of the present invention can be used to suppress inflammation and arthralgia. The food and beverage composition of the present invention can also be used to suppress bone resorption activity. The present invention also provides a novel composition for inhibiting bone resorption comprising chicken extract as an active ingredient. The peptide consisting of the amino acid sequence represented by SEQ ID NO: 1 and / or a salt thereof, and the chicken extract can be ingested as food and beverage products, etc., and have the advantage of being highly safe.

Claims

1. A type II collagen hydrolysate of chicken cartilage containing a peptide having an amino acid sequence represented by Gly-Pro-Glu-Gly-Ala-Pro-Gly-Lys-Asp (SEQ ID NO: 1) and / or a salt thereof, and A chicken extract containing one or more of carnosine and / or anserine and / or salts thereof, the weight ratio of the total weight of the carnosine, anserine and their salts in terms of carnosine and anserine to the weight of the peptide and / or its salt in terms of peptide (total weight of carnosine and anserine / peptide) is 1,000,000 / 1 to 1 / 15,000; A food or drink composition used to suppress inflammation.

2. The food and beverage composition according to claim 1, wherein the weight ratio of the total weight of the carnosine, anserine and their salts in terms of carnosine and anserine to the weight of the peptide and / or its salt in terms of peptide (total of carnosine and anserine / peptide) is 1,000,000 / 1 to 100 / 1.

3. The food and beverage composition according to claim 1 or 2, which suppresses production of at least one cytokine selected from the group consisting of macrophage inflammatory protein-1 (MIP-1), monocyte chemotactic protein-1 (MCP-1), interleukin-6 (IL-6), interleukin-7 (IL-7), interleukin-8 (IL-8), interleukin-9 (IL-9), interleukin-12 (IL-12), and RANTES (regulated on activation, normal T cell expressed and secreted).

4. The food or drink composition according to any one of claims 1 to 3, which is used for preventing or improving an inflammatory condition or disease.

5. The food or drink composition according to any one of claims 1 to 4, which is used to inhibit the bone resorption activity of osteoclasts.

6. The food or drink composition according to any one of claims 1 to 5, which is used for preventing or improving a condition or disease associated with bone mass loss.

7. The food and beverage composition according to claim 6, wherein the condition or disease associated with bone mass loss is osteoporosis or osteopenia.

8. A method for producing a collagen hydrolysate of chicken cartilage comprising the steps of: blending a peptide having an amino acid sequence represented by Gly-Pro-Glu-Gly-Ala-Pro-Gly-Lys-Asp (SEQ ID NO: 1) and / or a salt thereof; The method for producing the food and beverage composition according to any one of claims 1 to 7, comprising a step of blending a chicken extract containing one or more of carnosine and / or anserine and / or salts thereof.

9. Use of a type II collagen hydrolysate from chicken cartilage containing a peptide having an amino acid sequence represented by Gly-Pro-Glu-Gly-Ala-Pro-Gly-Lys-Asp (SEQ ID NO: 1) and / or a salt thereof for the production of an anti-inflammatory composition, comprising: The composition comprises a chicken extract containing one or more of carnosine and / or anserine and / or salts thereof, A use in which the weight ratio of the total weight of the carnosine, anserine and their salts in terms of carnosine and anserine to the weight of the peptide and / or its salt in terms of peptide in the composition (total weight of carnosine and anserine / peptide) is 1,000,000 / 1 to 1 / 15,000.

10. Use of a peptide having an amino acid sequence represented by Gly-Pro-Glu-Gly-Ala-Pro-Gly-Lys-Asp (SEQ ID NO: 1) and / or a salt thereof for producing a composition for inhibiting bone resorption, comprising: The composition comprises a chicken extract containing one or more of carnosine and / or anserine and / or salts thereof, A use in which the weight ratio of the total weight of the carnosine, anserine and their salts in terms of carnosine and anserine to the weight of the peptide and / or its salt in terms of peptide in the composition (total weight of carnosine and anserine / peptide) is 1,000,000 / 1 to 1 / 15,000.

Citation Information

Patent Citations

  • Dietary nutritious supplementary for preventing osteoarticular diseases of middle aged and elderly people

    CN103609935A

  • Therapeutic agent of arthropathy, and functional food

    JP2003048850A

  • Preventive agent or therapeutic agent of osteoporosis

    JP2003192610A

  • Peptides having anti-inflammatory activity, and compositions containing the same

    JP2015525768A

  • Bone metabolism improver

    JP2017226649A